FLT3 inhibitors for the treatment of autoimmune disease

Abstract

Background: Autoimmune diseases encompass a broad range of illnesses with a variety of underlying causes, some of which are known and some of which remain elusive.

Objective: The focus of this review will be on describing the development of a new type of therapy that could potentially treat T cell-mediated autoimmune diseases. Unlike traditional therapies, which have primarily focused on suppressing T cells directly, targeting the step of antigen presentation may allow a less toxic therapy in which autoimmunity is lessened without compromising the entire immune system. This review will outline the science behind the development of the therapy, the roles of dendritic cells in generating autoimmune disease, and the function of the FLT3 receptor in this process.

Figure 1

Manipulating DC function as a means to maintain beneficial immune responses while eliminating harmful ones.

Figure 2

FLT3 signaling as a target for DCs.